PF-Atlas › Clinical Trials › NCT03489629

STaph Aureus Resistance-Treat Early and Repeat

Trimethoprim Sulfamethoxazole · Phase 2

Registry ID
NCT03489629
Phase
Phase 2
Status
Completed
Drug / intervention
Trimethoprim Sulfamethoxazole (TMP/SMX)
Sponsor
University of North Carolina, Chapel Hill
Start
2018-04-03
Enrollment
37
Locations
9

About this trial

To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.

View NCT03489629 on ClinicalTrials.gov →

Explore related

All Trimethoprim Sulfamethoxazole trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03489629 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.